Randomised controlled trial to evaluate tolerance of a new high energy product with vitamins, minerals and protein in subjects in need of high caloric oral nutritional support.

1. Subjects (male/female) ≥ 18 years of age at the start of the Baseline period;

2. Subject is prescribed high caloric oral nutritional support (subject can be current or new user);

3. In case of new users: MUST (Malnutrition Universal Screening Tool) score 1 (medium risk of malnutrition), or 2 or more (high risk of malnutrition);

4. Subject is expected to require high caloric oral nutritional support for at least 4 weeks;

5. Subject has given written informed consent;

6. Subject is able to comply with the protocol (e.g. answer questions).

1. Known inflammatory bowel disease (e.g. Crohn's disease);

2. Pancreatitis or illness with known fat malabsorption;

3. Exposure to chemotherapy concomitantly or within two weeks prior to entry into the study;

4. Life expectancy of ≤ 3 months;

5. Known major hepatic dysfunction: symptomatic hepatic dysfunction or previous serum transaminase (ALAT, ASAT, or alkaline phosphatase) levels more than 5 times upper limit of normal;

6. Known major renal dysfunction: symptomatic renal dysfunction, previous serum creatinine level more than 1.8 times upper limit of normal, or requiring dialysis;

7. Ileostomy or colostomy;

8. Known galactosaemia;

9. Know cow's milk allergy;

10. Parenteral feeding;

11. Tube feeding;

12. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements;

13. Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.